Autonomix Medical Inc. has announced an increase in the aggregate sales price of its common stock under an existing At Market Issuances Sales Agreement with Ladenburg Thalmann & Co. Inc. The company has raised the sales limit by $1.4 million, allowing for additional sales of shares through the agreement. These transactions will be conducted under the company's "shelf" registration statement on Form S-3, which became effective in March 2025. The related prospectus supplement was filed with the Securities and Exchange Commission on August 25, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-027890), on August 27, 2025, and is solely responsible for the information contained therein.